Innovent Biologics Expands Portfolio with New Drug Approval

Innovent Biologics (HK:1801) has released an update.

Innovent Biologics has received approval from China’s National Medical Products Administration for its new drug, DOVBLERON, a next-generation ROS1 inhibitor for treating advanced ROS1-positive non-small cell lung cancer. This addition bolsters Innovent’s portfolio and offers a promising option for patients with limited treatment choices. The approval follows successful trials demonstrating DOVBLERON’s efficacy in addressing unmet needs in lung cancer treatment.

For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.